Not Signed In - Palatin Technologies And King Pharmaceuticals Report Results For Two Phase 2B Clinical Trials Evaluating Bremelanotide
Tue, 07 Nov 2006 08:00 AM EST
... Palatin Technologies, Inc. (Amex: PTN) and King Pharmaceuticals, Inc. (NYSE: KG) announced today positive results from two Phase 2B trials evaluating bremelanotide for the treatment of male erectile dysfunction (ED). The two Phase 2B clinical trials were double-blind, placebo-controlled, parallel dose trials that included a one month run-in period and a three-month treatment period. [click link for full article] ...
Related Topics
- Clinical Trials
- Ribavirin and Interferon alfa-2b, recombinant
- Pharmacology
- Psychopharmacology
- Carcinogens
- Interferon Alfa-2b
- Surgeon General's Reports on Tobacco
- Evaluating Health Information
- Speech & Communication Disorders
- Peginterferon alfa-2b
- Food Recommendations: South Beach Diet - Phase 1
- Food Recommendations: South Beach Diet - Phase 2
- Clinical Growth Charts
- Morbidity & Mortality Weekly Report
- Brain injury that results in physical, emotional, or intellectual changes or deficits
- Dilation And Curettage
- Pediatric Aids
- General Health
- Hypnotherapy
- Epidemiology
email this page
print this page
bookmark this page
feedback on this page
